Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome

Hematological Oncology
Christopher B BentonGuillermo Garcia-Manero

Abstract

Trabectedin is an FDA-approved DNA minor groove binder that has activity against translocation-associated sarcomas. Lurbinectedin is a next-generation minor groove binder with preclinical activity against myeloid leukemia cells. A dose-finding phase 1 clinical trial was performed in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with further assessment of safety and tolerability. Forty-two patients with relapsed/refractory AML/MDS received lurbinectedin administered as a 1-hour intravenous infusion in a 3 + 3 study design. Two dosing schedules were used: 3.5, 5, 7, or 6 mg on days 1 and 8 or 2, 3, 1, or 1.5 mg for 3 consecutive days on days 1 to 3. Three patients experienced dose-limiting toxicities of rhabdomyolysis (grade 4), hyperbilirubinemia (grade 3), and oral herpes (grade 3) with the day 1 and 8 schedule. Otherwise, adverse events mainly consisted of gastrointestinal manifestations (n = 11), febrile neutropenia/infections (n = 4), pulmonary toxicity (n = 2), and renal failure (n = 2). The most common laboratory abnormalities observed were an increase in creatinine (93%) and anemia, neutropenia, and thrombocytopenia (100%). Overall, 33 of 42 patients (79%) had reduction in blasts in periphe...Continue Reading

References

Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Mar 31, 2009·Cancer Treatment Reviews·Xuemei CaiDaniel D Von Hoff
Oct 28, 2010·British Journal of Pharmacology·J F M LealC M Galmarini
Feb 12, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jean-Yves BlaySant P Chawla
Feb 25, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·María Elena ElezMark J Ratain
Jan 23, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ana Teresa AmaralKatia Scotlandi
Sep 16, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George D DemetriShreyaskumar R Patel
Jan 11, 2017·British Journal of Cancer·Michela RomanoMaurizio D'Incalci
Sep 8, 2017·Immunotherapy·Hiromasa KurodaTadashi Kimura
Sep 30, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E CalvoM Forster

❮ Previous
Next ❯

Citations

Mar 20, 2021·Future Oncology·Javier BaenaLuis Paz-Ares
Aug 21, 2021·Bioorganic & Medicinal Chemistry·Thais Cristina Mendonça Nogueira, Marcus Vinicius Nora de Souza

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.